Mechanistically, we show that targeting MALAT1 induces DSBs and apoptosis, which makes prostate cancer cells vulnerable to DNA repair inhibitors, such as olaparib, and DNA-damaging agents like doxorubicin. Here, MALAT1 is linked to prostate carcinoma.